Institution
Stony Brook University
Education•Stony Brook, New York, United States•
About: Stony Brook University is a education organization based out in Stony Brook, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 32534 authors who have published 68218 publications receiving 3035131 citations. The organization is also known as: State University of New York at Stony Brook & SUNY Stony Brook.
Papers published on a yearly basis
Papers
More filters
••
Stanford University1, Fred Hutchinson Cancer Research Center2, Wayne State University3, Ohio State University4, Stony Brook University5, University of California, Irvine6, Memorial Hospital of Rhode Island7, University of Wisconsin-Madison8, University of Texas Health Science Center at San Antonio9, University of California, Davis10, Memorial Hospital of South Bend11, University of California, Los Angeles12
TL;DR: Treatment with CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with prior hysterectomy, however, treatmentWith CEE increases the frequency of mammography screening requiring short interval follow-up, and initiation of CEE should be based on consideration of the individual woman's potential risks and benefits.
Abstract: ContextThe Women's Health Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopped early because of an increased stroke incidence and no reduction in risk of coronary heart disease. Preliminary results suggesting possible reduction in breast cancers warranted more detailed analysis.ObjectiveTo determine the effects of CEE on breast cancers and mammographic findings.Design, Setting, and ParticipantsFollowing breast cancer risk assessment, 10 739 postmenopausal women aged 50 to 79 years with prior hysterectomy were randomized to CEE or placebo at 40 US clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included.InterventionA dose of 0.625 mg/d of CEE or an identical-appearing placebo.Main Outcome MeasuresBreast cancer incidence, tumor characteristics, and mammogram findings.ResultsAfter a mean (SD) follow-up of 7.1 (1.6) years, the invasive breast cancer hazard ratio (HR) for women assigned to CEE vs placebo was 0.80 (95% confidence interval [CI], 0.62-1.04; P = .09) with annualized rates of 0.28% (104 cases in the CEE group) and 0.34% (133 cases in the placebo group). In exploratory analyses, ductal carcinomas (HR, 0.71; 95% CI, 0.52-0.99) were reduced in the CEE group vs placebo group; however, the test for interaction by tumor type was not significant (P = .054). At 1 year, 9.2% of women in the CEE group had mammograms with abnormalities requiring follow-up vs 5.5% in the placebo group (P<.001), a pattern that continued through the trial to reach a cumulative percentage of 36.2% vs 28.1%, respectively (P<.001); however, this difference was primarily in assessments requiring short interval follow-up.ConclusionsTreatment with CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with prior hysterectomy. However, treatment with CEE increases the frequency of mammography screening requiring short interval follow-up. Initiation of CEE should be based on consideration of the individual woman's potential risks and benefits.Trial Registrationclinicaltrials.gov Identifier: NCT00000611
558 citations
••
TL;DR: The substrates for YopJ were shown to be highly conserved ubiquitin-like molecules, which are covalently added to numerous regulatory proteins, which exert their pathogenic effect on cells by disrupting this posttranslational modification.
Abstract: Homologs of the Yersinia virulence effector YopJ are found in both plant and animal bacterial pathogens, as well as plant symbionts. These YopJ family members were shown to act as cysteine proteases. The catalytic triad of the protease was required for inhibition of the mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) signaling in animal cells and for induction of localized cell death in plants. The substrates for YopJ were shown to be highly conserved ubiquitin-like molecules, which are covalently added to numerous regulatory proteins. YopJ family members exert their pathogenic effect on cells by disrupting this posttranslational modification.
557 citations
••
TL;DR: A novel transcription-independent proapoptotic function mediated by the cytoplasmic pool of p53 has been revealed and p53 participates directly in the intrinsic apoptosis pathway by interacting with the multidomain members of the Bcl-2 family to induce mitochondrial outer membrane permeabilization.
557 citations
••
557 citations
••
TL;DR: It is shown, by direct nano-infrared imaging, that these hyperbolic polaritons can be effectively modulated in a van der Waals heterostructure composed of monolayer graphene on h-BN.
Abstract: Hexagonal boron nitride (h-BN) is a natural hyperbolic material, in which the dielectric constants are the same in the basal plane (e(t) ≡ e(x) = e(y)) but have opposite signs (e(t)e(z) < 0) in the normal plane (e(z)). Owing to this property, finite-thickness slabs of h-BN act as multimode waveguides for the propagation of hyperbolic phonon polaritons--collective modes that originate from the coupling between photons and electric dipoles in phonons. However, control of these hyperbolic phonon polaritons modes has remained challenging, mostly because their electrodynamic properties are dictated by the crystal lattice of h-BN. Here we show, by direct nano-infrared imaging, that these hyperbolic polaritons can be effectively modulated in a van der Waals heterostructure composed of monolayer graphene on h-BN. Tunability originates from the hybridization of surface plasmon polaritons in graphene with hyperbolic phonon polaritons in h-BN, so that the eigenmodes of the graphene/h-BN heterostructure are hyperbolic plasmon-phonon polaritons. The hyperbolic plasmon-phonon polaritons in graphene/h-BN suffer little from ohmic losses, making their propagation length 1.5-2.0 times greater than that of hyperbolic phonon polaritons in h-BN. The hyperbolic plasmon-phonon polaritons possess the combined virtues of surface plasmon polaritons in graphene and hyperbolic phonon polaritons in h-BN. Therefore, graphene/h-BN can be classified as an electromagnetic metamaterial as the resulting properties of these devices are not present in its constituent elements alone.
557 citations
Authors
Showing all 32829 results
Name | H-index | Papers | Citations |
---|---|---|---|
Zhong Lin Wang | 245 | 2529 | 259003 |
Dennis W. Dickson | 191 | 1243 | 148488 |
Hyun-Chul Kim | 176 | 4076 | 183227 |
David Baker | 173 | 1226 | 109377 |
J. N. Butler | 172 | 2525 | 175561 |
Roderick T. Bronson | 169 | 679 | 107702 |
Nora D. Volkow | 165 | 958 | 107463 |
Jovan Milosevic | 152 | 1433 | 106802 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Paolo Boffetta | 148 | 1455 | 93876 |
Jacques Banchereau | 143 | 634 | 99261 |
Larry R. Squire | 143 | 472 | 85306 |
John D. E. Gabrieli | 142 | 480 | 68254 |
Alexander Milov | 142 | 1143 | 93374 |
Meenakshi Narain | 142 | 1805 | 147741 |